Comparative outcomes of budesonide mmx versus prednisolone for ulcerative colitis: Results from a British retrospective multi‐centre real‐world study
Authors
Rosiou, KOng Ming San, E
Kumar, Aditi
Esquivel, Kim
Almas, Saima
Stokes, Daniel
Ng, Tze
Jayasooriya, Nishani
Ranasinghe, Ian
Pollok, Richard
Brookes, Matthew

Selinger, Christian
Issue Date
2021-09-23
Metadata
Show full item recordAbstract
During the COVID‐19 pandemic many IBD units chose Budesonide MMX (Cortiment) as the first‐line treatment for flares of ulcerative colitis (UC) in outpatients for its favourable side effect profile. This retrospective study of all UC patients treated with oral steroids between 1 March 2019– 30 June 2019 and 1 March 2020–30 June 2020 aimed to compare Cortiment with Prednisolone in routine clinical practice. Outcomes included the need for hospitalisation for acute severe ulcerative colitis, symptoms at four weeks and end of treatment, and the need for rescue Prednisolone. The 2019 and 2020 cohorts did not differ at the baseline. Cortiment prescriptions rose from 24.5% in 2019 to 70.1% in 2020 (p < 0.001). At week four there were significant differences between 2019 and 2020 in mean bowel frequency (3.49 vs. 5.85, p = 0.001), rectal bleeding <50% (89.7% vs. 73.1% of patients, p = 0.039), and physician global assessment (PGA) (39.2% vs. 19.8% in remission, p = 0.045). There was no significant difference in hospital admissions, rectal bleeding, and PGA at week eight. Rescue Prednisolone was required in 10% of Cortiment patients in 2019 vs. 31.3% in 2020 (p = 0.058). Active IBD is associated with worse COVID‐19 outcomes prompting the careful evaluation of the choice of first‐line steroid for UC, as Cortiment was associated with worse outcomes at four weeks.Citation
Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. (2021) Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. Journal of Clinical Medicine, 10(19):4329. https://doi.org/10.3390/jcm10194329Publisher
MDPIJournal
Journal of Clinical MedicinePubMed ID
34640345 (pubmed)Type
Journal articleLanguage
enDescription
© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/jcm10194329ISSN
2077-0383EISSN
2077-0383ae974a485f413a2113503eed53cd6c53
10.3390/jcm10194329
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
Related articles
- Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study.
- Authors: Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP
- Issue date: 2021 Sep 23
- A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®(MMX®)) for active, mild-to-moderate ulcerative colitis.
- Authors: Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L
- Issue date: 2019 Nov
- Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
- Authors: Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL
- Issue date: 2018 Sep
- Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.
- Authors: Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L
- Issue date: 2016